Expertise in
33
conditions

Dr. Michael J. Tansey

Pediatric Endocrinology | Pediatrics | Endocrinology
State University Of Iowa
200 Hawkins Dr, 
Iowa City, IA 
Accepting New Patients
Expertise in
33
conditions
State University Of Iowa
200 Hawkins Dr, 
Iowa City, IA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Tansey is a Pediatric Endocrinologist and a Pediatrics provider in Iowa City, Iowa. Dr. Tansey is highly rated in 33 conditions, according to our data. His top areas of expertise are Type 1 Diabetes (T1D), Prader-Willi Syndrome, Langer Mesomelic Dysplasia, and Microcephalic Osteodysplastic Primordial Dwarfism Type 1 (MOPD1). Dr. Tansey is currently accepting new patients.

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Endocrinology
Pediatrics
Endocrinology
Licenses
Pediatric Endocrinology in IA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Sanford Health
  • HMO
  • PPO
Wellmark
  • HMO
  • POS

Locations

STATE UNIVERSITY OF IOWA
200 Hawkins Dr, Iowa City, IA 52242

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus
INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 06, 2025
Intervention Type: Biological
Study Drugs: Afrezza, Rapid-acting Insulin Analog, Basal Insulin
Study Phase: Phase 3
A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Idiopathic Growth Hormone Deficiency (GHD)
A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Idiopathic Growth Hormone Deficiency (GHD)
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drugs: LUM-201, rhGH Norditropin® pen
Study Phase: Phase 2
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Terminated
Publish Date: April 09, 2024
Intervention Type: Drug
Study Drug: Hydroxychloroquine
Study Phase: Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
Enrollment Status: Terminated
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drug: RAD011
Study Phase: Phase 2/Phase 3
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus
Enrollment Status: Active_not_recruiting
Publish Date: November 09, 2020
Intervention Type: Other, Biological
Study Drug: TOL-3021
Study Phase: Phase 2
View 4 Less Clinical Trials

33 Total Publications

Differences in White Matter Microstructure in Children With Type 1 Diabetes Persist During Longitudinal Follow-up: Relation to Dysglycemia.
Differences in White Matter Microstructure in Children With Type 1 Diabetes Persist During Longitudinal Follow-up: Relation to Dysglycemia.
Journal: Diabetes
Published: August 09, 2024
Similar Doctors
Expertise in
2
conditions
Dr. Eva Tsalikian
Pediatric Endocrinology | Endocrinology
Expertise in
2
conditions
Dr. Eva Tsalikian
Pediatric Endocrinology | Endocrinology
200 Hawkins Dr, 
Iowa City, IA 
 (0.1 mi)
319-356-1833
Languages Spoken:
English, French, Greek, Spanish
See accepted insurances
Accepting New Patients

Eva Tsalikian is a Pediatric Endocrinologist and an Endocrinologist in Iowa City, Iowa. Dr. Tsalikian is highly rated in 2 conditions, according to our data. Her top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, and Diabetic Ketoacidosis. Dr. Tsalikian is currently accepting new patients.

Expertise in
3
conditions
Dr. Catherina T. Pinnaro
Pediatric Endocrinology | Pediatrics | Endocrinology
Expertise in
3
conditions
Dr. Catherina T. Pinnaro
Pediatric Endocrinology | Pediatrics | Endocrinology
200 Hawkins Dr, 
Iowa City, IA 
 (0.1 mi)
319-353-7370
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Catherina Pinnaro is a Pediatric Endocrinologist and a Pediatrics provider in Iowa City, Iowa. Dr. Pinnaro is highly rated in 3 conditions, according to our data. Her top areas of expertise are Turner Syndrome, Intersex, Mosaicism, and Triple X Syndrome. Dr. Pinnaro is currently accepting new patients.

Expertise in
24
conditions
Dr. Janet A. Schlechte
Endocrinology
Expertise in
24
conditions
Dr. Janet A. Schlechte
Endocrinology
200 Hawkins Dr, 
Iowa City, IA 
 (0.1 mi)
319-384-8305
Languages Spoken:
English
See accepted insurances

Janet Schlechte is an Endocrinologist in Iowa City, Iowa. Dr. Schlechte is highly rated in 24 conditions, according to our data. Her top areas of expertise are Melorheostosis, Osteopenia, Melorheostosis with Osteopoikilosis, and Osteoporosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tansey's expertise for a condition
ConditionClose
    View All 32 Advanced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile